Cosmo Pharmaceuticals has announced impressive topline results from its two pivotal Phase 3 trials evaluating clascoterone 5% topical solution for male androgenic alopecia (AGA). These data mark what may be the first major therapeutic breakthrough for male-pattern hair loss in over 30 years. What is Clascoterone? Clascoterone is a topical androgen receptor inhibitor designed to … Continue reading Cosmo has Announced Phase III Topline Results for Clascoterone 5% Solution in the Treatment of Androgenic Alopecia